Widespread Distribution of Xylazine Detected Throughout the United States in Healthcare Patient Samples
Open Access
- 6 January 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 17 (4) , 468-470
Abstract
Objectives: Xylazine is a tranquilizer commonly added into the illicit drug supply and a likely contributor to overdoses because it does not respond to naloxone reversal. The objective of this study was to perform a retrospective data analysis on xylazine-positive samples collected from patients in various outpatient healthcare settings to illustrate geographic distribution and common copositive substances, which may also contribute to risk of adverse events. Methods: Samples for which providers ordered testing for xylazine were subjected to enzymatic hydrolysis, extracted, and analyzed using liquid chromatography–tandem mass spectrometry. Retrospective analysis was performed on xylazine-positive samples collected from April 2021 to March 2022, to include geographic location and copositive substances. Results: Xylazine was identified in 413 of 59,498 samples from adults aged 20–73 years and originated from 25 of the 39 states where xylazine testing was ordered. The most common routine substances detected with xylazine were fentanyl, buprenorphine, naloxone, cocaine, d-methamphetamine, and delta-9-tetrahydrocannabinol. The most common designer drugs detected included fentanyl analogs, isotonitazene, and designer benzodiazepines. Conclusions: Xylazine is geographically spread throughout the United States, indicative of a wide incorporation into the illicit drug supply. These findings differ from previous studies in that these samples originated from healthcare providers in routine care settings, where other reports typically involve overdose deaths. This analysis illustrates that routine testing for xylazine in outpatient settings can afford providers the opportunity to educate individuals and adjust harm reduction measures to potentially mitigate overdose risk.Keywords
This publication has 11 references indexed in Scilit:
- Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology CaseworkJournal of Analytical Toxicology, 2022
- Notes From the Field: Xylazine-Related Deaths — Cook County, Illinois, 2017–2021MMWR. Morbidity and Mortality Weekly Report, 2022
- Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisisDrug and Alcohol Dependence, 2022
- Notes from the Field: Xylazine Detection and Involvement in Drug Overdose Deaths — United States, 2019MMWR. Morbidity and Mortality Weekly Report, 2021
- Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019Injury Prevention, 2021
- Xylazine, a Veterinary Tranquilizer, Detected in 42 Accidental Fentanyl Intoxication DeathsAmerican Journal of Forensic Medicine & Pathology, 2020
- Xylazine Exposures Reported to Texas Poison CentersThe Journal of Emergency Medicine, 2016
- Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literatureForensic Science International, 2014
- Xylazine – a review of its pharmacology and use in veterinary medicineJournal of Veterinary Pharmacology and Therapeutics, 1988
- Human Xylazine Overdose: A Comparative Review with Clonidine, Phenothiazines, and Tricyclic AntidepressantsClinical Toxicology, 1981